Tsefurus powder for solution for injection 1.5g vial 1 piece

$3.81

Tsefurus powder for solution for injection 1.5g vial 1 piece

Quantity:

Description

Composition
Active substance:
1 vial contains: cefuroxime sodium (calculated as cefuroxime) – 0.75 g or 1.5 g
Product form:
powder for solution for intravenous and intramuscular injection of 0.75 g and 0.75 g of 1,5 g of active substance in 10 ml capacity vials, 1.5 g of active substance in 20 ml capacity vials, hermetically sealed with rubber stoppers, crimped caps aluminum or aluminum caps combined with plastic lids. 1, 5 or 10 units with instructions for use placed in a pile of cardboard. 50 vials with an equal number of instructions for use are placed in a box made of cardboard for delivery to hospitals. 1 vial of 10 mL capacity with a preparation of 0.75 g of 2 vials with the solvent (5 ml of water for injection) are placed in blisters of PVC film. 1 contour cell package with instructions for use and a lancet ampoule is placed in a pile of cardboard. 1 vial of 10 mL capacity with a preparation of 0.75 g of 2 with a solvent ampoule, and instructions for use scarifier ampoule was placed in a pack or box made of cardboard. 5 vials of 10 mL capacity with a preparation of 0.75 g is placed in blisters of PVC film. 1 contour cell package with a preparation of 0.75 g of 2 blisters (5 vials solvent) instructions for use, scarifier ampoule is placed in a pile of cardboard. When using ampoules with a ring or a break-point and notched scarifier ampoule not invest.
Contraindications
Hypersensitivity to cefuroxime (including to other. Cephalosporins, carbapenems and penicillins).
Dosage
1500 mg
Indications
Bacterial infections caused by microorganisms sensitive to cefuroxime: – respiratory diseases (bronchitis, pneumonia, lung abscess, empyema); – upper respiratory tract (sinusitis, tonsillitis, pharyngitis, otitis media); – urinary tract infection (pyelonephritis, cystitis, asymptomatic bacteriuria); – skin and soft tissues (erysipelas, pyoderma, impetigo, furunculosis, cellulitis, wound infection, pseudoerysipelas); – bones and joints (osteomyelitis, septic arthritis); – pelvic organs (endometritis, adnexitis, cervicitis); – sepsis; – meningitis; – gonorrhea; – Lyme disease (Lyme disease); – prevention of infectious complications during thoracic operations organs, abdomen, pelvis, joints (including the operations in the lung, heart, esophagus, in vascular surgery at high risk of infectious complications, orthopedic surgery).
Interaction with other drugs
The simultaneous appointment of “loop” diuretics slows tubular secretion and reduces renal clearance, increases the concentration in plasma and increases the half-life of cefuroxime. While the use of aminoglycosides and diuretics increased risk of nephrotoxic effects. Pharmaceutically compatible with aqueous solutions containing up to 1% lidocaine hydrochloride, 0.9% sodium chloride, 5 and 10% dextrose, 0.18% sodium chloride and 4% dextrose, 5% dextrose and 0.9% sodium chloride solution, Ringer’s solution , Hartman solution, sodium lactate solution, heparinized (10 U / ml and 50 U / ml) in 0.9% sodium chloride solution. Pharmaceutically compatible with aminoglycosides, sodium bicarbonate solution 2.74%.
Overdose
Symptoms: excitation of the central nervous system, convulsion.
Treatment: symptomatic, hemodialysis, peritoneal dialysis.
pharmachologic effect
Pharmacological group:
Cephalosporin antibiotic.
Pharmacodynamics:
Cefuroxime belongs to the cephalosporin antibiotics II generation. Cefuroxime is active against a broad spectrum of pathogens, including strains that produce beta-lactamase. The bactericidal action of cefuroxime associated with suppression of bacterial cell wall synthesis. Cefuroxime is active in vitro against the following microorganisms: Gram Aerobes: Haemophilus influenzae (including ampitsillinrezistentnye strains); Haemophilus parainfluenzae (including ampitsillinrezistentnye strains); Moraxella catarrhalis; Escherichia coli; Klebsiella spp .; Proteus mirabilis; Providencia spp .; Providencia rettgeri; Neisseria gonorrhoeae (including penicillinase-producing strains and producing no penicillinase); Neisseria meningitidis; Salmonella spp .; Bordetella pertussis. Gram-positive aerobes: Staphylococcus aureus, Staphylococcus epidermidis (including strains resistant to penicillins and except for strains resistant to methicillin); Streptococcus pneumoniae; Streptococcus pyogenes (and other beta-hemolytic streptococci); Group B Streptococcus (Streptococcus agalactiae); Streptococcus mitis (viridans group). Anaerobes: Gram-positive and Gram-negative cocci (including Peptococcus and Peptostreptococcus species); Gram-positive bacilli (including species of Clostridium spp.); Gram-negative bacilli (including Bacteroides spp and Fusobacterium spp..); Propionibacterium spp. Other organisms: Borrelia burgdorferi. The following organisms are not susceptible to cefuroxime: Clostridium difficile; Pseudomonas spp .; Campylobacter spp .; Acinetobacter calcoaceticus; Listeria monocytogenes; methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis, Legionella spp .; Enterococcus faecalis; Morganella morganii; Proteus vulgaris; Enterobacter spp .; Citrobacter spp .; Serratia spp .; Bacteroides fragilis.
Pharmacokinetics:
Parenteral administration: after intramuscular injection of 0.75 g of maximum concentration (Cmax) is reached after 15-60 minutes, and was 27 ug / ml. When administered intravenously, 0.75 g and 1.5 g of the maximum concentration after 15 minutes was 50 and 100 ug / ml, respectively. A therapeutic concentration is 5.3 and 8 hours, respectively. The half-life (T1 / 2) for intravenous and intramuscular administration – 1.3-1.5 hours in newborn infants – 2-2.5 hours Connection to plasma proteins -. 33-50%. Therapeutic concentrations are recorded in the pleural fluid, bile, phlegm, myocardium, skin and soft tissues. Concentrations of cefuroxime in excess of the minimum inhibitory concentration for most microorganisms can be achieved in bone tissue, synovial fluid and aqueous humor. In meningitis penetrates the blood-brain barrier. It passes through the placenta and passes into breast milk. It is not metabolized in the liver. Excreted by the kidneys by glomerular filtration and tubular secretion of 85-90% unchanged for 8 h (most of the drug is excreted within the first 6 hours, creating a high concentration in urine); after 24 h is displayed in full (50% – by tubular secretion, 50% – by glomerular filtration).
Pregnancy and breast-feeding
Use of the drug during pregnancy and lactation is possible if the expected benefit to the mother outweighs the potential risk to the fetus and child.
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions: fever, rash, itching, rash, erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), bronchospasm, drug fever, serum sickness, anaphylaxis, cutaneous vasculitis.
Local reactions: intramuscular injection – pain, irritation and infiltration at the site of injection, by intravenous injection – phlebitis, thrombophlebitis.
From the nervous system: convulsions.
With the genitourinary system: an itch in the perineum, vaginitis.
Urinary System: disturbance of kidney function (with increased concentration of creatinine and / or BUN and decrease of creatinine clearance), dysuria, interstitial nephritis.
From the digestive system: diarrhea, constipation, flatulence, glossitis, nausea, vomiting, cramping and abdominal pain, ulceration of the oral mucosa, oral candidiasis, cholestasis, pseudomembranous colitis.
From the side of hematopoiesis: eosinophilia, leukopenia, neutropenia, thrombocytopenia, agranulocytosis, hemolytic anemia, decreased hemoglobin and hematocrit, hypoprothrombinemia, prolonged prothrombin time.
From the senses: hearing loss.
Laboratory findings: increased activity of “liver” enzymes (alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase), hyperbilirubinemia, false positive Coombs test.
special instructions
Patients who had a history of allergic reaction to penicillin can be hypersensitivity to cephalosporin antibiotics.
During treatment requires monitoring of renal function, especially in patients receiving the drug in high doses, in elderly patients with a history of kidney disease, while the use of aminoglycosides and “loop” diuretics.
Treatment was continued for 48-72 hours after the disappearance of symptoms, in the case of infections caused by Streptococcus pyogenes, a course of treatment – at least 7-10 days. During treatment possible false-positive direct Coombs’ test and false positive reaction on urine glucose.
In patients receiving cefuroxime, the determination of the concentration of blood glucose is recommended to use tests with glucose oxidase or hexokinase. Pseudomembranous colitis is observed when using broad-spectrum antibiotics, the possibility of its occurrence must be borne in mind in patients with severe diarrhea, occurred during or after a course of antibiotic treatment.
During treatment can not use ethanol.
The treatment of meningitis in children is possible hearing loss. In the transition from parenteral administration to oral administration should take into account the severity of the infection, the sensitivity of the microorganisms and the general status of the patient. If there is no clinical response after 72 hours of starting treatment, the parenteral course of treatment must be continued.
Ready-to-use solution may be stored at room temperature for 7 hours in the refrigerator -. For 48 hours is allowed to use for yellowed during storage solution.
Effects on ability to drive vehicles and management mechanisms.
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In a dry, dark place at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Intramuscularly, intravenously.
Intravenous and intramuscular adults appoint 0.75 g three times a day; severe infections – dose increased to 1.5 g 3-4 times a day (the interval between doses can be shortened to 6 hours as necessary). The average daily dose – 3-6 g
Children older than 3 months appoint 30-100 mg / kg / day in 3-4 administration. In most infections optimum dose is 60 mg / kg / day.
Infants and children up to 3 months administered 30 mg / kg / day in 2-3 administration.
In gonorrhea – intramuscularly, adult 1.5 g once (in the form of two injections of 0.75 g of the introduction in different areas, for example in both gluteal muscle).
In bacterial meningitis – intravenous, adults – 3 g every 8 hours; children younger and older – 150-250 mg / kg / day in 3-4 introduction, newborn – 100 mg / kg / day in 2-3 administration.
To prevent postoperative complications: – for heart surgery, lung, esophagus and blood vessels – intravenous injection, 1.5 g of 0,5 – 1 hour before surgery and 0.75 g intravenously or intramuscularly every 8 hours during long operations over the next 24 – 48 hr (with open-heart operations total dose 6 g); – the operations in the abdomen, pelvis and orthopedic surgery – intravenous injection, 1.5 g of anesthesia induction, followed by further – intramuscularly 0.75 g, at 8 and 16 hours after surgery; -with total joint replacement – 1.5 g powder were mixed in dry form with each packet of the polymer cement before the addition of methyl methacrylate liquid monomer.
When pneumonia – intramuscularly or intravenously, for 1.5 g of 2-3 times a day for 48-72 h, then move on ingestion (using dosage forms for oral administration) 0.5 g of 2 times a day during 7-10 days.
During exacerbation of chronic bronchitis administered intramuscularly or intravenously at 0.75 g 2-3 times a day for 48-72 h, then move on ingestion (using dosage forms for oral administration) 0.5 g of 2 times a day for 5 -10 days.
In chronic renal failure requires a correction mode in adults: the creatinine clearance (CC) of 10-20 ml / min administered intravenously or intramuscularly to 0.75 g of 2 times a day, with CC less than 10 ml / min – of 0.75 g of 1 time per day . In chronic renal failure in children dosing regimen should be changed in accordance with the recommendations for adults. Patients in hemodialysis using a continuous high speed ICU arteriovenous shunt or hemofiltration, 0.75 g of 2 administered twice a day; for patients are on low speed hemofiltration, administered doses are recommended with impaired renal function.
Preparation of a suspension for intramuscular injection: 0.75 g (10 ml vial) dissolved in 3 ml of water for injection. 1.5 g (20 ml vial) dissolved in 6 ml of water for injection. Carefully shaking to form a suspension.
Preparation of solution for intravenous injection: 0.75 g (10 ml vial) dissolved in 9 mL of water for injection. 1.5 g (20 ml vial) dissolved in 14 ml of water for injection. A solution for intravenous infusion.
In the case of short intravenous infusion (e.g., up to 30 min) 1.5 g dissolved in 50 ml of water for injection. These solutions can be administered directly into a vein or IV, if a patient parenterally administered fluid.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

SYNTHESIS

There are no reviews yet.

Add your review